New: Evolving the Heatmap: Dow Jones, Nasdaq 100, Russell 2000, and More

5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

By Ekta Bagri | July 02, 2025, 9:28 AM

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Verona Pharma Plc ADR

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Exelixis, Inc. (EXEL): Free Stock Analysis Report

Alkermes plc (ALKS): Free Stock Analysis Report

Verona Pharma PLC American Depositary Share (VRNA): Free Stock Analysis Report

Kiniksa Pharmaceuticals International, plc (KNSA): Free Stock Analysis Report

Immunocore Holdings PLC Sponsored ADR (IMCR): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Mentioned In This Article

Immunocore Holdings plc ADR

Kiniksa Pharmaceuticals International Plc

Verona Pharma Plc ADR

Latest News

Sep-30	Verona Pharma plc (VRNA) Nears $10B Merck Buyout, Ohtuvayre Boosts COPD Portfolio VRNA Insider Monkey
Sep-30	Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years EXEL Motley Fool
Sep-29	Beat the Market the Zacks Way: Helios Technologies, InterDigital, UnitedHealth in Focus KNSA Zacks
Sep-27	Exelixis (EXEL) Rated Equalweight by Barclays Amid Cancer Drug Outlook EXEL Insider Monkey
Sep-26	Morgan Stanley Maintains Overweight Rating For Exelixis, Inc. (EXEL), Price Target Raised To $50 EXEL Insider Monkey
Sep-26	CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program KNSA Zacks
Sep-26	CarMax downgraded, Kenvue upgraded: Wall Street's top analyst calls ALKS The Fly
Sep-25	QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study KNSA Zacks
Sep-25	ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure KNSA Zacks
Sep-25	Here's What Lifted Verona Pharma (VRNA) in Q2 VRNA Insider Monkey
Sep-24	REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug KNSA Zacks
Sep-24	Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience KNSA Zacks
Sep-23	5 Biotech Stocks Worth Adding to Your Portfolio Now KNSA Zacks
Sep-22	SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU KNSA Zacks
Sep-22	FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug Filing KNSA Zacks

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.